Lidocaine HCl/Phenylephrine HCl Nasal Solution Recalled for CGMP Deviations
Edge Pharma, LLC is recalling Lidocaine HCl/Phenylephrine HCl Nasal Solution (4%/1%) nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The recall involves 231 bottles.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II recall from the FDA involving manufacturing practice deviations. No illnesses, injuries, or deaths are reported in the source text, and the hazard is regulatory/manufacturing-based rather than from confirmed product contamination or defect. Per the rubric, FDA Class II without hospitalization or injury reports is typically Moderate (score 2).
Plain-English summary
Edge Pharma, LLC is voluntarily recalling Lidocaine HCl/Phenylephrine HCl Nasal Solution, 4%/1%, 240 mL per bottle, in multiple-dose containers, due to Current Good Manufacturing Practice (CGMP) deviations. The product is identified by NDC 05446-1045-03 and was manufactured by Edge Pharma, LLC in Colchester, Vermont.
The recall affects 231 bottles that were distributed nationwide. The affected product lot codes and dates are: 07-2021-02@7 (distributed 12-29-2021), 07-2021-23@4 (distributed 01-19-2022), 08-2021-11@7 (distributed 02-07-2022), 08-2021-23@8 (distributed 02-19-2022), and 09-2021-24@10 (distributed 03-23-2022).
Consumers who have purchased this product should stop using it and contact their healthcare provider or pharmacist for guidance. The recall was initiated by the firm on December 6, 2021, and was classified as Class II by the FDA on January 24, 2022.
The recalled product
- Product
- Lidocaine HCl/Phenylephrine HCl Nasal Solution, 4%/1%, 240 mL per bottle, Multiple Dose Container, Edge Pharma, LLC 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1045-03
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Nasal Solution
- Hazard
- Affected units
- 231
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- 07-2021-02@7 12-29-2021
- 07-2021-23@4 01-19-2022
- 08-2021-11@7 02-07-2022
- 08-2021-23@8 02-19-2022 & 09-2021-24@10 03-23-2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 56 recalled by Edge Pharma, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 56 products in this recall →Related recalls
Same manufacturer · Edge Pharma, LLC
See all →- ModerateProfound-PE Dental Gel Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-02-02
- SevereMVASI Sterile Ophthalmic Solution Lacks Assured Sterility
FDA (Drugs) · 2022-02-02
- ModerateLET Topical Gel drug recall for CGMP deviations
FDA (Drugs) · 2022-02-02
- SevereVancomycin HCl Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2022-02-02
- ModerateCSF-HC Otic Powder Drug Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-02-02
Same hazard · cgmp deviation
See all →- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Clindamycin Phosphate Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09